Track: Preventive Cardiology and Cardiovascular Risk Reduction
Despite decades of effective antihypertensive and lipid-lowering therapy, atherosclerotic cardiovascular disease remains the world's leading cause of premature death, demanding upstream precision prevention strategies. The Preventive Cardiology & Cardiovascular Risk Reduction session at Heart Congress 2027 examines polygenic risk scores for early ASCVD identification, PCSK9 inhibitors and inclisiran in very high-risk populations, and the landmark SELECT trial establishing cardiovascular mortality benefits of GLP-1 receptor agonists in overweight patients without diabetes. The session also addresses emerging RNA-targeted therapies for lipoprotein(a) reduction, bempedoic acid in statin-intolerant patients, anti-inflammatory cardiovascular risk reduction with colchicine, and the social determinants driving cardiovascular health inequity.
Key Discussion Areas:
• Polygenic risk scores (PRS) for early ASCVD risk prediction
• PCSK9 inhibitors and inclisiran: LDL lowering in very high-risk populations
• Cardiovascular benefits of GLP-1 receptor agonists: SELECT trial and beyond
• Lipoprotein(a): pelacarsen, olpasiran and emerging RNA-targeted therapies
• Bempedoic acid and non-statin lipid-lowering in statin intolerance
• Inflammatory cardiovascular risk: colchicine, IL-1β inhibition, and hsCRP
• Lifestyle medicine: dietary patterns, exercise prescription, and cardiovascular reversal
• Social determinants of cardiovascular health and health equity in prevention
Why Attend This Session?
Preventive cardiologists, lipidologists, endocrinologists, and primary care physicians will gain a comprehensive update on evidence-based risk stratification tools, emerging lipid-lowering and anti-inflammatory therapies, and cardiometabolic risk management strategies applicable across diverse patient populations.
Related Topics:
• Cardiometabolic Syndrome & Diabetes in Cardiology
• Cardiac Imaging & Advanced Diagnostics
• Heart Failure & Cardiomyopathies
Frequently Asked Questions:
1. What is the importance of preventive cardiology and cardiovascular risk reduction in cardiovascular medicine?
Preventive Cardiology and Cardiovascular Risk Reduction plays a significant role in improving diagnosis, treatment strategies, patient outcomes, and clinical decision-making in modern cardiology.
2. What are the latest trends in preventive cardiology and cardiovascular risk reduction?
Recent trends include precision medicine, AI-assisted diagnostics, minimally invasive therapies, digital healthcare technologies, and personalized patient management.
Scientific Highlights
- Preventive Cardiology and Cardiovascular Risk Reduction
- Heart Failure and Advanced Cardiac Therapies
- Interventional Cardiology and Structural Heart Disease
- Cardiac Electrophysiology and Arrhythmia Management
- Acute Coronary Syndromes
- Cardiovascular Imaging and Multimodality Diagnostics
- Cardiomyopathies: Genetics, Phenotyping, and Treatment
- Cardio Oncology
- Cardiometabolic Disease, Lipidology, and Atherosclerosis
- Hypertension and Renal Cardiovascular Interactions
- Digital Health, AI, and the Future of Cardiology
- Pediatric and Congenital Cardiology
- Vascular Medicine and Aortic Diseases
- Women's Cardiovascular Health and Sports Cardiology
- Precision Medicine, Genomics, and Regenerative Cardiology
- Cardiovascular and Cardiothoracic Surgery
- Cardiovascular Case Studies and Clinical Insights
- Emergency and Critical Cardiac Care
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Conference Enquiry - Kristina Pierce
kristinapierce@scientexconferences.com
General Enquiry
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
cardiacsurgery@scientexevents.org
Our Social Presence
Call us at
USA : (+1) 272 374 1068